Carole Huntsman serves as the Chief Commercial Officer at Madrigal Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. In her role, Huntsman is responsible for overseeing the company's commercial strategy and operations, including the launch and market penetration of Madrigal's lead product candidate, resmetirom. Her expertise in pharmaceutical commercialization has been instrumental in guiding Madrigal through the complex process of bringing a new therapy to market, ensuring that the company is well-positioned to meet the needs of patients and healthcare providers. Prior to joining Madrigal, Huntsman held several senior leadership positions in the pharmaceutical industry. She spent over a decade at Vertex Pharmaceuticals, where she played a key role in the successful launch of multiple blockbuster drugs, including Incivek for hepatitis C and Orkambi for cystic fibrosis. Her strategic vision and operational excellence were critical to the company's growth and success during her tenure. Before Vertex, Huntsman worked at Pfizer, where she gained valuable experience in global marketing and sales, further solidifying her reputation as a seasoned commercial leader in the pharmaceutical sector. Huntsman's achievements extend beyond her corporate roles. She is recognized for her thought leadership in the industry, frequently speaking at conferences and contributing to discussions on the future of pharmaceutical commercialization. Her ability to navigate the challenges of drug development and market entry has made her a respected figure in the field. At Madrigal, Huntsman's leadership continues to drive the company forward, as she works tirelessly to ensure that resmetirom reaches the patients who need it most, potentially transforming the treatment landscape for NASH and improving countless lives.